New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector
Executive Summary
With nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company's Smartinhaler to improve outcomes for children with poorly controlled asthma should boost the pairing of digital technologies with drugs.
You may also be interested in...
Video Interview: Adherium mHealth Device Helps Pharma Boost Patient Compliance
Garth Sutherland, CEO of Adherium Ltd, tells Mike Ward, global director of content of Informa's pharma insights portfolio, about Adherium's endeavor in the digital health space. Sutherland outlines how the B2B digital health company, listed in Australia last year, is selling its Smartinhaler technology to big pharma, hospitals and disease management companies. The platform itself is made up of a cloud-based server that harbors data collected by Adherium's Smartinhaler, a medical device that records drug usage and can be clipped onto any prescribed inhaler used to treat asthma and COPD. Not only can the patient view the data collected on their smart phone or tablet, it can also be accessed by the patient's medical providers. Moreover, along with the data collection, the device provides patients with audio and visual reminders to take their medication.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.